OPKO Health
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, OPKO Health sits in the top decile of US sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count).
OPKO Health: 32 sponsored US clinical trials, none currently recruiting.
OPKO Health sponsors 32 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 25 completed. 4 of these trials are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Growth Hormone Deficiency (GHD), with 1 trials.
Top-decile sponsor footprint
OPKO Health ranks in the top decile of sponsors by registered trial count (#513 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 31 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
32 total, page 1 of 1
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
NCT07494045
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
NCT05543928
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
NCT04551911
A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations
NCT03810664
Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects
NCT03660800
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
NCT03602261
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
NCT03588884
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
NCT03406377
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
NCT03297398
4Kscore Using Serum Stored Uncentrifuged
NCT04130776
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT02968004
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
NCT02418793
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
NCT02418767
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
NCT02274623
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
NCT02119819
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT02500316
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
NCT01791725
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01766336
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
NCT01735630
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
NCT01674010
Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
NCT01357421
Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
NCT01219855
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
NCT00934050
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
NCT00743002
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
NCT00499590
Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
NCT00384098
Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
NCT00306904
A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
NCT00239187
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
NCT00259753
A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
NCT00239148
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
NCT00722384
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 18 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Therapeutic Areas
How the OPKO Health early-phase archive is shaped
32 indexed studies, none listed as recruiting (0% open); 25 completed (78%).
Phase mix: 4 late (III/IV) vs 27 early (I/II) (early-phase heavy).
Top condition: Growth Hormone Deficiency (GHD) (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
OPKO Health: archived-pipeline peers nationwide
Peers matched on 32 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
OPKO Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 32 archived trials
- Aerie Pharmaceuticals · 32 trials · 0% recruiting
- Allina Health System · 32 trials · 3% recruiting
- Ardea Biosciences · 32 trials · 0% recruiting
- Hebrew SeniorLife · 32 trials · 19% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this OPKO Health page
32 registered trials is a research-attention snapshot, not an endorsement of OPKO Health or any single study.
- None of OPKO Health's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Growth Hormone Deficiency (GHD) is the condition OPKO Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Growth Hormone Deficiency (GHD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. OPKO Health pipeline card: 32 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.